New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
HIGHER: Intercept (ICPT), up 46% after upgraded at Leerink and Citigroup following OCA data. Conatus Pharmaceuticals (CNAT), which also develops treatments for liver disease, up 8.5%... Fontegra Financial (FRF), up 40% after Tiptree Financial (TIPT) to acquire the company for $10.00 per share in cash... Insys Therapeutics (INSY), up 15.4% after submiting NDA for new formula of Dronabinol Oral Solution, saying it is on track to submit at least four IND applications with the FDA in the second half of 2014... Exact Sciences (EXAS), up 8% after announcing FDA approved for Cologuard... Abercrombie & Fitch (ANF), up 2.7% after upgraded at Stifel. UP AFTER EARNINGS: Kate Spade (KATE), up 5.5%... Noah Holdings (NOAH), up 3%... ReneSola (SOL), up 5%... Supernus (SUPN), up 14%. LOWER: NII Holdings (NIHD), down 54.5% after warning it needs to make "key decisions" to address liquidity, "likely" to file a voluntary petition for relief under Chapter 11 of the Bankruptcy Code... Dendreon (DNDN), down 23.6% after warning that its alternatives could leave shareholders with no ownership... magicJack (CALL), down 10.3%, downgraded at Canaccord following Q2 results... Hi-Crush Partners (HCLP), down 4.7% after filing to sell 3.26M common units representing limited partners... Triangle Capital (TCAP), down 3.8% after filing to sell 4M shares of common stock. DOWN AFTER EARNINGS: Nuance (NUAN), down 9.4%... Flowers Foods (FLO), down 7.8%.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 30, 2015
16:05 EDTTIPTBlackstone completes acquisition of Tiptree Financial subsidiary
Subscribe for More Information
10:00 EDTANFOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Abercrombie & Fitch (ANF) downgraded to Market Perform from Outperform at FBR Capital... Apollo Education (APOL) downgraded on enrollment uncertainty at BofA/Merrill... Flagstar Bancorp (FBC) downgraded to Hold from Buy at Sandler O'Neill... Global Brass and Copper (BRSS) downgraded to Hold from Buy at BB&T... HSBC (HSBC) downgraded to Neutral from Buy at Goldman... Herman Miller (MLHR) downgraded to Neutral at Longbow... NiSource (NI) downgraded on valuation, post spinoff outlook at Argus... Sysco (SYY) downgraded to Hold from Buy at Deutsche Bank... TCF Financial (TCB) downgraded to Hold from Buy at Sandler O'Neill.
09:13 EDTKATECowen lowers handbag estimates, calls Kate Spade favorite name in space
Subscribe for More Information
08:52 EDTINSYInsys Therapeutics price target raised to $46 from $38 at Piper Jaffray
Subscribe for More Information
07:02 EDTANFAbercrombie & Fitch downgraded to Market Perform from Outperform at FBR Capital
FBR Capital downgraded Abercrombie & Fitch to Market Perform and maintained its $24 price target. The firm said store productivity could be pressured across segments as the brand image turnaround is a ways out and may require a new generation of consumers. FBR said sweeping cultural changes are positive but benefits will take time, there is potential for continued margin pressure from international, and the teen/young adult industry is in a multiyear transition.
June 29, 2015
16:13 EDTICPTIntercept submits applications for marketing approval of Obeticholic Acid
Subscribe for More Information
June 26, 2015
13:46 EDTEXASFly Watch: Exact Sciences predicted to jump if task force update favorable
The US Preventive Services Task Force, or USPSTF, is expected to publish its revised guidelines for colorectal cancer, or CRC, screening in the third quarter of 2015. The guidelines should include an assessment of Exact Sciences' (EXAS) Cologuard, an "easy to use, noninvasive colon cancer screening test." ANALYST TAKE: The USPSTF guidelines were noted as "the last binary event for Cologuard" by Jefferies and "the major overhang" for Exact Sciences by Mizuho Securities. Jefferies analyst Brandon Couillard and his team, which rate Exact Sciences a Buy with a $33 price target, see "significant upside" from a favorable outcome and said their thesis was boosted by confident comments from a "former affiliate of the USPSTF's review board." Mizuho analysts Peter Lawson and Eric Criscuolo, who rate Exact Sciences a Buy with a $35 price target, said they believe Cologuard will receive an "A" or "B" rating from the USPSTF, triggering further adoption by mandating coverage of Cologuard by private insurance. Baird defended Exact Sciences after the stock dropped 5.5% on Thursday, June 25, saying Exact Sciences' investor relations day was "bullish" in tone as the company provided a "deep dive" update on its Cologuard launch. Baird maintained its Outperform rating and $44 price target on the company. PRICE ACTION: Over the past week, shares of Exact Sciences are up more than 5% despite Thursday's 5.5% pullback. Over the last month, shares are up about 12% and over the last three months they are higher by almost 40%.
08:18 EDTEXASExact Sciences recent weakness unwarranted, says Baird
Subscribe for More Information
07:17 EDTEXASExact Sciences compelling as a platform growth company, says Canaccord
Subscribe for More Information
June 25, 2015
14:14 EDTANFAbercrombie & Fitch, DoJ settle immigration related employment case
Subscribe for More Information
11:09 EDTINSYInsys sinks after nurse pleads guilty to receiving kickbacks
Subscribe for More Information
08:03 EDTEXASExact Sciences to host analyst and investor day with a conference call hookup
Subscribe for More Information
07:09 EDTCNATConatus announces initial baseline data from Phase 2b POLT-HCV-SVR trial
Conatus announced pre-treatment biomarker and histology data from the first 16 patients enrolled in the company's Phase 2b clinical trial of its lead drug candidate, emricasan, in post-orthotopic liver transplant, or POLT, recipients. These patients have reestablished liver fibrosis or cirrhosis post-transplant as a result of recurrent hepatitis C virus, or HCV, infection and have successfully achieved a sustained viral response, or SVR, following HCV antiviral therapy, or POLT-HCV-SVR. Among the first 16 patients enrolled, more than 85% achieved SVRs using recently approved oral HCV antiviral treatments. The excitement generated by these new treatments altered enrollment patterns during the early stage of the POLT-HCV-SVR trial, and their rapid market penetration is now expanding the trial-eligible population. The double-blind, placebo-controlled trial was initiated in May 2014 in patients with Ishak Fibrosis Scores of 2 to 4. Consistent with the company's initial registration focus on the development of a treatment for cirrhosis, the trial was expanded in early 2015 to include patients with Ishak 5 and is currently expanding to Ishak 6. Patients are being randomized 2:1 to receive either 25 mg of emricasan or placebo orally twice daily for 24 months and will be followed for another month post-treatment. The primary endpoint in this exploratory proof-of-concept trial is the change in the Ishak Fibrosis Score compared with placebo. The trial will also evaluate histological markers of inflammation, key serum biomarkers, and the safety and tolerability of emricasan in the target patient population. Enrollment of approximately 60 total planned patients is on track for release of final top-line results in the first half of 2018.
06:34 EDTEXASExact Sciences' Cologuard shows strong sales in Q2
Subscribe for More Information
June 24, 2015
11:16 EDTHCLPHi-Crush Partners management to meet with Jefferies
Meetings to be held in Dallas/Kansas City on June 30-July 1 hosted by Jefferies.
07:18 EDTHCLPCredit Suisse to hold a conference
2015 MLP & Energy Logistics Conference is being held in New York on June 23-24 with webcasted company presentations to begin on June 24 at 8 am; not all company presentations may be webcasted. Webcast Link
June 23, 2015
07:36 EDTANFJMP Securities to hold a conference
Subscribe for More Information
June 22, 2015
07:53 EDTEXASExact Sciences estimates raised ahead of analyst Day at Canaccord
Canaccord raised its estimates on Exact Sciences ahead of June 26 Analyst Day. The firm cited the impact from the 160-person sales force addition from Ironwood Pharmaceuticals and pipeline opportunities beyond Cologuard for the increase. Canaccord raised its price target to $32 from $30 on Exact Sciences shares.
June 19, 2015
08:40 EDTEXASJefferies sees significant upside for Exact Sciences on positive USPSTF review
Subscribe for More Information
June 18, 2015
06:43 EDTSUPNSupernus price target raised to $20 from $16 at Piper Jaffray
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use